Finch Therapeutics Group, Inc. (FNCH) is a publicly traded company in the Unknown sector. Across all available filings, 7 corporate insiders have executed 31 transactions totaling $31.4M, demonstrating a bullish sentiment with $31.4M in net insider flow. The most recent transaction on Jun 7, 2024 involved a transaction of 383 shares valued at $0.
No significant insider buying has been recorded for FNCH in the recent period.
No significant insider selling has been recorded for FNCH in the recent period.
Based on recent SEC filings, insider sentiment for FNCH is bullish with an Insider Alignment Score of 100/100 and a net flow of $31.4M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Finch Therapeutics Group, Inc. (FNCH) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 7 insiders are actively trading FNCH stock, having executed 31 transactions in the past 90 days. The most active insider is Nicholas Haft (Executive), who has made 8 transactions totaling $15.6M.
Get notified when executives and directors at FNCH file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jun 7, 2024 | A. Smisek Jeffery | Executive | Gift | 383 | $N/A | $0 | |
| Jun 7, 2024 | A. Smisek Jeffery | Executive | Gift | 384 | $N/A | $0 | |
| May 20, 2024 | A. Smisek Jeffery | Executive | Gift | 3,750 | $N/A | $0 | |
| Mar 28, 2024 | A. Smisek Jeffery | Executive | Sale | 1,600 | $2.61 | $4.2K | |
| Mar 28, 2024 | A. Smisek Jeffery | Executive | Sale | 6,642 | $2.57 | $17.1K | |
| Nov 22, 2023 | A. Smisek Jeffery | Executive | Sale | 1,470 | $3.64 | $5.4K | |
| Jun 9, 2023 | E. Graf Susan | Executive | Purchase | 5,010 | $0.27 | $1.4K | |
| Feb 21, 2023 | Blaustein Marc | Executive | Sale | 4,619 | $0.38 | $1.8K | |
| Oct 21, 2022 | Vittiglio Joseph | Executive | Sale | 3,636 | $1.39 | $5.1K | |
| Oct 21, 2022 | Blaustein Marc | Executive | Sale | 3,636 | $1.39 | $5.1K | |
| Jun 13, 2022 | Vittiglio Joseph | Executive | Award | 35,000 | $N/A | $0 | |
| Jun 13, 2022 | Blaustein Marc | Executive | Award | 35,000 | $N/A | $0 | |
| Dec 20, 2021 | Haft Nicholas | Executive | Purchase | 63,850 | $10.18 | $650.0K | Large |
| Mar 23, 2021 | Llc Crestovo Investor | Executive | Purchase | 735,294 | $17.00 | $12.5M | Large |
| Mar 23, 2021 | Llc Crestovo Investor | Executive | Conversion | 11,906,147 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 6 | $31.4M | 99.9% |
Sale(S) | 6 | $38.5K | 0.1% |
Gift(G) | 3 | $0 | 0.0% |
Award(A) | 2 | $0 | 0.0% |
Conversion(C) | 14 | $0 | 0.0% |
Insiders at Finch Therapeutics Group, Inc. are accumulating shares at an accelerated pace. With 7 insiders making 31 transactions totaling $31.4M in purchases versus $38.5K in sales, the net buying activity of $31.4M signals strong executive confidence. Nicholas Haft (Executive) leads the buying activity with $15.6M in transactions across all time.